GlassScriptPhysician profile
Tiffany E Escobar
NPI 1053821686
$3,265.72
in general payments reported to CMS, 2019-2025
23 companies · $184 in 2025
The $184 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $727 · 2022: $298 · 2023: $370 · 2024: $1,687 · 2025: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,358 · Travel and Lodging: $883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,357.81 |
| Travel and Lodging | $882.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,534.92 | 2021-2025 | Intracept, Superion Indirect Decompression System, Wavewriter Alpha Prime 16 |
| Abbott Laboratories | $437.94 | 2021-2024 | Proclaim, Eterna |
| Medtronic, INC. | $215.90 | 2021-2022 | |
| Averitas Pharma INC. | $151.83 | 2024 | Qutenza |
| Abbvie INC. | $138.64 | 2021-2024 | |
| Amgen INC. | $121.76 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $79.99 | 2021 | |
| Allergan, INC. | $74.38 | 2021 | |
| Lilly USA, LLC | $59.48 | 2021-2022 | |
| Curonix LLC | $54.30 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Scilex Pharmaceuticals INC. | $48.85 | 2021-2025 | |
| Almatica Pharma LLC | $44.17 | 2021 | |
| Globus Medical, INC. | $42.84 | 2025 | Senza |
| Saluda Medical Americas, INC. | $42.08 | 2025 | Evoke |
| Nevro Corp. | $40.36 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grt US Holding, INC. | $32.50 | 2022 | |
| Pacira Therapeutics, INC. | $31.02 | 2021 | |
| Fidia Pharma USA INC. | $29.90 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $23.39 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $20.69 | 2025 | |
| Novartis Pharmaceuticals Corporation | $16.02 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.08 | 2023 | Seglentis |
| Astrazeneca Pharmaceuticals LP | $11.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Escobar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.